Company name Dova Pharmaceuticals, Inc.
Stock symbol DOVA
Status Under Investigation

NEW YORK, September 30, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) on behalf of Dova shareholders concerning the proposed merger with Swedish Orphan Biovitrum AB.

Pursuant to the proposed transaction, announced on September 30, 2019 and valued at $915 million, Dova shareholders will receive $27.50 in cash for each share of Dova common stock owned.  Additionally, Dova shareholders will be entitled to one non-tradeable CVR of $1.50 per share upon the regulatory approval of DOPTELET, a treatment for CIT.  The investigation focuses on whether Dova and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.

If you own Dova shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Alexandra Raymond by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

First name*

Last name*

City, state, ZIP code

Email address*

Daytime phone

Evening phone

Purchase Date

No. of Shares

Purchase Price

Purchase Date

No. of Shares

Purchase Price

Join action?
YesNo


Call to provide more information: Tel: (212) 355-4648

Please list below any additional transactions in this security:

Additional comments

The submission of this form does not create an attorney-client relationship, nor any obligation on the part of Bragar Eagel & Squire, P.C., or you to file a legal action. Any information you submit will be maintained as confidential. If Bragar Eagel & Squire, P.C., in its sole discretion, believes that you might be an appropriate class representative, Bragar Eagel & Squire, P.C., will contact you to discuss the matter and to determine whether to establish an attorney client relationship.